Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Holdings Included in FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years

TOKYO, July 10, 2025 - ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo / President, Representative Director: Sohta Yamaguchi, hereinafter "ASKA") is pleased to announce that ASKA has been included in the FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for consecutive years.

About FTSE Blossom Japan Index (ASKA has been Included for three consecutive years)

Created by the global index and data provider FTSE Russell, the FTSE Blossom Japan Index is designed as an industry neutral benchmark that reflects the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices in Japan.
FTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption and Climate Change. Businesses included in the FTSE Blossom Japan Index meet a variety of environmental, social and governance criteria.

About FTSE Blossom Japan Index (ASKA has been Included for four consecutive years)

The FTSE Blossom Japan Sector Relative Index is designed as a sector neutral benchmark that reflects the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices in Japan. The index selects companies with higher ESG Ratings within the top 50% of each sector and supports climate transition to a low carbon economy by evaluating companies' climate governance and climate change efforts via the Transition Pathway Initiative's Management Quality Score.

In April 2021, ASKA took a new step forward with the transition to a holding company structure. ASKA works to solve social issues through its business based on the corporate philosophy: "contribute toward the improvement of people's health and progress in society through the development of innovative products." In April 2023, ASKA strengthened its structure by appointing a Board member in charge of sustainability and establishing a specialized department within the Corporate Planning Department to accelerate its efforts to date further. In 2024, ASKA Pharmaceutical Co., Ltd., the core subsidiary of the Company, began receiving electricity generated by photovoltaic power generation through on-site PPA at Iwaki Factory and implemented environmentally friendly packaging changes for Pharmaceutical products. In these ways, the Group continues to address ESG issues. ASKA will continue to work proactively to resolve these issues in the future to achieve sustainable growth and enhance its corporate value over the medium to long term.

About FTSE Russell

FTSE Russell is a global index provider offering innovative benchmarking, analysis, and data solutions to investors around the world. It calculates various ESG indices using ESG and climate change data. It also provides a variety of information and analytical services to institutional investors, including ESG scores and other data, industry classifications (ICB), issue codes (SEDOL), and analytical tools.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp